<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03347786</url>
  </required_header>
  <id_info>
    <org_study_id>GNI_verap</org_study_id>
    <nct_id>NCT03347786</nct_id>
  </id_info>
  <brief_title>Verapamil for Neuroprotection in Stroke</brief_title>
  <official_title>Intraarterial Verapamil for Neuroprotection in Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Global Neurosciences Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Global Neurosciences Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to test an experimental procedure called intra-arterial&#xD;
      delivery of verapamil in patients diagnosed with acute ischemic stroke. This study&#xD;
      investigates the safety of intra-arterial delivery of verapamil, a drug used to treat&#xD;
      vasospasm (spasm of a blood vessel), and how it affects recovery from stroke. Recruitment is&#xD;
      limited to patients that have received mechanical thrombectomy as standard of care.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2017</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serious Adverse Event</measure>
    <time_frame>3 months</time_frame>
    <description>Death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious Adverse Event</measure>
    <time_frame>3 months</time_frame>
    <description>Hemorrhagic conversion</description>
  </primary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Ischemic Stroke</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verapamil</intervention_name>
    <description>Intra-arterial delivery of verapamil following mechanical thrombectomy procedure</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  18 years of age and over&#xD;
&#xD;
          -  Acute onset focal neurologic deficit consistent with acute ischemic stroke, or&#xD;
             computed tomographic scan consistent with acute cerebral ischemia&#xD;
&#xD;
          -  Candidate for mechanical thrombectomy procedure&#xD;
&#xD;
          -  Onset of symptoms less than 8 hours&#xD;
&#xD;
          -  Measurable neurologic deficit (NIHSS &gt;1)&#xD;
&#xD;
          -  Willingness to follow up with rehabilitation therapy&#xD;
&#xD;
          -  Anticipated life expectancy of at least 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or suspected pregnancy (pregnancy test will be done on women of&#xD;
             child-bearing potential)&#xD;
&#xD;
          -  Hepatic and/or renal insufficiency (LFT's&gt;3Ã— upper limit of normal; CrCl &lt; 30ml/min)&#xD;
&#xD;
          -  Thrombocytopenia (platelet count &lt;75,000/mm3)&#xD;
&#xD;
          -  History of intolerance to verapamil&#xD;
&#xD;
          -  Previous functional disability (modified Rankin &gt; 1)&#xD;
&#xD;
          -  Stuporous or comatose&#xD;
&#xD;
          -  Unlikely to be available for 90 day follow-up&#xD;
&#xD;
          -  Severe stroke (NIHSS&gt;22)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Our Lady of Lourdes Medical Center</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Maxwell</last_name>
      <phone>215-762-6915</phone>
      <email>cmaxwell@gnineuro.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hahnemann University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Maxwell</last_name>
      <phone>215-762-6915</phone>
      <email>cmaxwell@gnineuro.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Crozer Keystone Health System</name>
      <address>
        <city>Upland</city>
        <state>Pennsylvania</state>
        <zip>19013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Maxwell</last_name>
      <phone>215-762-6915</phone>
      <email>cmaxwell@gnineuro.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 9, 2017</study_first_submitted>
  <study_first_submitted_qc>November 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2017</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Global Neurosciences Institute</investigator_affiliation>
    <investigator_full_name>Erol Veznedaroglu</investigator_full_name>
    <investigator_title>Director, Global Neurosciences Institute</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Verapamil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD will not be shared as this is a pilot study to determine safety</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

